- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03436485
Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer (CYPIDES)
January 26, 2024 updated by: Orion Corporation, Orion Pharma
The purpose of this first-in-man study is to evaluate safety and tolerability of ODM-208 in patients with metastatic castration-resistant prostate cancer.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
Safety and tolerability profile of ODM-208 will be explored
Study Type
Interventional
Enrollment (Estimated)
204
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Orion Corporation Clinical Study director
- Phone Number: 3288 +358 10 4261
- Email: clinicaltrials@orionpharma.com
Study Contact Backup
- Name: Orion Corporation, CSD
Study Locations
-
-
-
Helsinki, Finland
- Helsinki University Central Hospital
-
Tampere, Finland
- Tampere University Hospital
-
-
-
-
-
Bordeaux, France
- Institute Bergonie
-
Lyon, France
- Centre Leon Berard
-
Marseille, France
- Institute Paoli-Calmettes
-
Strasbourg, France
- Institut de cancerologie Strasbourg Europe
-
Suresnes, France, 92150
- Hopital Foch
-
Villejuif, France
- Institut Gustave Roussy
-
-
-
-
-
Bedlington, United Kingdom
- The Rutherford Cancer Centre, North East
-
Cardiff, United Kingdom, CF14 2TL
- Velindre Cancer Centre
-
Glasgow, United Kingdom, G12 0YN
- The Beatson West of Scotland Cancer Centre
-
Liverpool, United Kingdom
- The Rutherford Cancer Centre, North West
-
London, United Kingdom, SW3 6JJ
- Royal Marsden Hospital
-
London, United Kingdom
- Charing Cross Hospital
-
Manchester, United Kingdom
- The Christie NHS Foundation Trust
-
Preston, United Kingdom, PR2 9HT
- Royal Preston Hospital
-
-
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- University of Maryland Marlene and Stewart Greenebaum Cancer Center
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Masonic Cancer Center, University of Minnesota
-
-
Nebraska
-
Omaha, Nebraska, United States, 68114
- Nebraska Cancer Specialists
-
-
New York
-
Buffalo, New York, United States, 14203
- University at Buffalo, Kaleida Health Great Lakes Cancer Care Collaborative
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Main Inclusion Criteria:
- Written informed consent (IC) obtained.
- Male aged ≥ 18 years.
- Histologically confirmed adenocarcinoma of the prostate.
- Castration resistant prostate cancer with serum testosterone < 50 ng/dl.
- Metastatic disease.
- Ongoing androgen deprivation therapy with GnRH analogue or antagonist, or have had bilateral orchiectomy.
- Received at least one prior line of novel hormonal androgen receptor (AR) targeted therapy (e.g. abiraterone, enzalutamide).
- ECOG performance status 0-1.
- Adequate marrow, liver and kidney function.
- Able to swallow study treatment.
- Part 1: Treatment with at least 1 line of chemotherapy or ineligibility for chemotherapy. Part 2: Treatment with at least 1 line of taxane-based chemotherapy in castration-sensitive prostate cancer (CSPC) or in CRPC.
Main Exclusion Criteria:
- History of pituitary or adrenal dysfunction.
- Known brain metastases or active leptomeningeal disease.
- Active infection or other medical condition that would make corticosteroid contraindicated.
- Poorly controlled diabetes.
- Hypotension or uncontrolled hypertension.
- Clinically significantly abnormal serum potassium or sodium level.
- Active or unstable cardio/cerebro-vascular disease including thromboembolic events.
- Prolonged QTcF interval.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ODM-208 Part 1 Dose escalation
|
co-administered with glucocorticoid and fludrocortisone, orally daily
|
Experimental: ODM-208 Part 2 Dose expansion
|
co-administered with glucocorticoid and fludrocortisone, orally daily
|
Experimental: ODM-208 Part 2 Drug drug interaction
|
co-administered with glucocorticoid and fludrocortisone, orally daily
orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum tolerated dose (MTD)
Time Frame: Within first 28 days of treatment
|
Highest dose level at which under 33% of patients in a cohort experience DLT
|
Within first 28 days of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Karim Fizazi, Gustave Roussy, Cancer Campus, Grand Paris
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 19, 2018
Primary Completion (Estimated)
December 1, 2024
Study Completion (Estimated)
December 1, 2024
Study Registration Dates
First Submitted
February 12, 2018
First Submitted That Met QC Criteria
February 12, 2018
First Posted (Actual)
February 19, 2018
Study Record Updates
Last Update Posted (Estimated)
January 29, 2024
Last Update Submitted That Met QC Criteria
January 26, 2024
Last Verified
January 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Tranquilizing Agents
- Psychotropic Drugs
- Hypnotics and Sedatives
- Adjuvants, Anesthesia
- Anti-Anxiety Agents
- GABA Modulators
- GABA Agents
- Midazolam
Other Study ID Numbers
- 3124001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer Metastatic
-
Imperial College LondonWellcome Trust; Imperial Clinical Trials Unit (ICTU)CompletedProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Metastatic Prostate Carcinoma in the Soft Tissue | Non-metastatic Prostate CancerUnited Kingdom
-
Dana MathewsWithdrawnProstate Cancer | Prostate Cancer Metastatic | Prostate Cancer Metastatic to BoneUnited States
-
The University of Texas Health Science Center at...WithdrawnMetastatic Prostate Cancer | Prostate Cancer Metastatic | Metastatic Prostate Adenocarcinoma | Castrate Resistant Prostate CancerUnited States
-
Herlev and Gentofte HospitalBristol-Myers SquibbRecruitingProstate Cancer Metastatic | Metastatic Castration-resistant Prostate Cancer | Castrate Resistant Prostate Cancer | Prostate Cancer Stage IVDenmark
-
Myovant Sciences GmbHRecruitingMetastatic Castration-Resistant Prostate Cancer | Metastatic Castration-Sensitive Prostate Cancer | Non-Metastatic Castration-Resistant Prostate CancerUnited States
-
Dana-Farber Cancer InstituteEpizyme, Inc.; PfizerRecruitingMetastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Bellicum PharmaceuticalsSuspendedMetastatic Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States
-
Tavanta TherapeuticsCompletedMetastatic Prostate Cancer | Metastatic Castration-sensitive Prostate Cancer | Metastatic Castration-resistant Prostate CancerUnited States, Spain, United Kingdom, Hungary, France, Poland, Puerto Rico, Sweden
-
Memorial Sloan Kettering Cancer CenterProgenics Pharmaceuticals, Inc.RecruitingProstate Cancer | Metastatic Prostate Cancer | Prostate Adenocarcinoma | Prostate Cancer Metastatic | Prostate NeoplasmUnited States
-
Vadim S KoshkinEli Lilly and Company; Prostate Cancer FoundationActive, not recruitingCastration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Castration-resistant Prostate Cancer | Metastatic Prostate Adenocarcinoma | Metastatic Castration-resistant Prostate CarcinomaUnited States
Clinical Trials on ODM-208
-
Zeria PharmaceuticalCompletedAdvanced Hepatocellular CarcinomaJapan
-
Addpharma Inc.Completed
-
Resverlogix CorpWithdrawn
-
Resverlogix CorpCompletedSafety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL CholesterolCardiovascular Disease | Atherosclerosis | Dyslipidemia | Acute Coronary SyndromeUnited States
-
Orion Corporation, Orion PharmaEndo PharmaceuticalsCompleted
-
Orion Corporation, Orion PharmaCompleted
-
Orion Corporation, Orion PharmaCompletedProstate CancerUnited States, United Kingdom, Finland, France, Estonia, Czech Republic
-
Resverlogix CorpNucleus Network Ltd; Baker Heart and Diabetes InstituteCompleted
-
Orion Corporation, Orion PharmaQuotient ClinicalCompleted
-
Allon TherapeuticsCompletedMild Cognitive ImpairmentUnited States, Canada